GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Japan and China. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales. The China segment covers the integrated bio-pharma operations consisting of validation, preclinical trials, formulation, phase I to III clinical trials, manufacturing and sales. The company was founded on November 20, 2001 and is headquartered in Tokyo, Japan.